Palo Alto Networks Inc (PANW) Stock Price Today
Aura AI Summary
Key Stats
- $261.28BMARKET_CAP
- -VOLUME
- TechnologySECTOR
- $357.53FIFTY_TWO_WEEK_HIGH
- $141.67FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $260.24BENTERPRISE_VALUE
- -DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Palo Alto Networks Inc (PANW) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Palo Alto Networks Inc has traded between a low of $141.67 and a high of $357.53, highlighting its annual price range. Buy and sell Palo Alto Networks Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Most Recent News
Global digital ad market to hit $2T by 2033, driven by AI and budget shifts to retail and CTV ads
The global digital advertising market is forecasted to grow from $567.9 billion in 2025 to $2.06 trillion by 2033, with a 17.6% CAGR. Growth is fueled not just by expansion but by a strategic reallocation of budgets toward digital platforms offering ...

SK Hynix debuts on Nasdaq July 10; GraniteShares launches 2x leveraged ETFs July 13
SK Hynix, a trillion-dollar South Korean chipmaker, will start trading on Nasdaq under the ticker SKHY on July 10, marking its first US listing. Following this, GraniteShares will launch two ETFs on July 13: a 2x long ETF (SKUU) and a 2x short ETF (S...

Medline faces securities fraud probe after FDA cites manufacturing violations, stock drops 7%.
Medline Industries is under investigation by Pomerantz LLP for potential securities fraud following an FDA warning about significant manufacturing violations. The FDA highlighted Medline's failure to properly investigate discrepancies in pharmaceutic...
